Financial Performance
Medicamen Biotech Limited reported strong financial results for FY 2025-26 with consolidated revenue growth of 21.66% to ₹197.77 crore and net profit of ₹9.80 crore, representing 49.43% growth year-over-year. Standalone performance showed revenue of ₹178.85 crore (18.08% growth) and PAT of ₹9.41 crore. The company recommended a final dividend of ₹1 per equity share (10% on face value) payable to shareholders on record date of September 19, 2026.
Capital Structure & Fundraising
The company completed significant capital raising activities including preferential allotment of 848,215 equity shares at ₹530 per share (total ₹44.96 crore) and issuance of 650,000 convertible warrants at ₹530 per warrant (potential ₹34.45 crore). Share capital increased to ₹13.56 crore with share premium reserve growing to ₹14.64 crore. The company maintained CRISIL ratings of BBB-/Stable for long-term and A3 for short-term borrowings.
Business Operations & Expansion
Medicamen's subsidiary Medicamen Lifesciences achieved 71% YoY sales growth in cardiovascular and diabetes therapies. The company expanded internationally with product registrations in Denmark and Norway, regulatory submissions in Europe, and CDMO projects for oncology. Manufacturing capabilities include three facilities totaling 277,000 sq. ft. with USFDA, EU, and WHO-GMP certifications. The oncology division strengthened presence across leading cancer care institutions including AIIMS Delhi and Tata Memorial Centre.
Corporate Governance & Compliance
The Board comprises 10 directors with appropriate independence. The company faced SEBI penalties for delayed shareholding pattern filing (₹7,080) and non-compliant committee composition (₹1,10,920). Auditors issued unqualified opinions confirming true and fair view of financial statements. Key compliance issues included excess related party transactions with Shivalik Rasayan, CSR calculation methodology discrepancies, and non-submission of POSH annual report.
AGM Agenda & Shareholder Matters
The 33rd Annual General Meeting is scheduled for September 26, 2026 via video conference with remote e-voting available September 23-25. Agenda items include adoption of financial statements, dividend declaration, director reappointments, ratification of cost auditor remuneration, and approval of material related party transactions with Shivalik Rasayan and Medicamen Lifesciences.
Subsidiary Performance
Medicamen Life Sciences Private Limited (60% subsidiary) reported revenue of ₹18.93 crore and PAT of ₹0.39 crore with total assets of ₹18.07 crore. Opal Pharmaceuticals Pty Ltd (100% subsidiary) in Australia showed minimal activity with assets of AUD 86,749.08.
Cash Flow & Financial Position
Net cash from operating activities was negative ₹33.17 crore while financing activities generated positive cash flow of ₹63.72 crore primarily from equity issuance. Cash and equivalents improved significantly to ₹31.26 crore from ₹3.76 crore in previous year. Total assets stood at ₹371.99 crore with equity of ₹275.55 crore.